IMMU (Da Paura)

Re: Re: Re: Re: piace anche a me...

Scritto da okkrim
non ne ho la piu' pallida idea Big ;)

direi di attendere una candela di inversione

quella di oggi conferma quella di venerdi...

a mio giudizio deve scaricare un poko

fra 7,95 e 8,40 c'e' un'area di forte supporto se non buca la', facile ke la ripartenza sia a breve...

ma a quanto non lo so...

ciao

io riterrei interessante un 8,20....
 
Re: Re: Re: Re: Re: piace anche a me...

Scritto da BigNick
io riterrei interessante un 8,20....

come lo determini 8,20?
 
Re: Re: Re: Re: Re: Re: piace anche a me...

Scritto da okkrim
come lo determini 8,20?

niente di particolare guardavo l'orario degli ultimi venti giorni, la media 50 mi sembrava un buon supporto...
 
a prima vista direi che non ha molta voglia di scendere

forse entrare ieri intorno agli 8,4 non era sbagliato.....vediamo oggi cosa combina...

ciao

BigNick
 

Allegati

  • immu2.gif
    immu2.gif
    31,3 KB · Visite: 314
non mi convince

la segui ancora Okkrim ?
 
Re: non mi convince

Scritto da BigNick
la segui ancora Okkrim ?

l'ho seguita oggi... ha fatto un balzo in intra...

neppure a me convince...

magari parte e non si ferma + :D

sto per fare un saltino con SVVS... ;)
 
Re: Re: non mi convince

Scritto da okkrim
l'ho seguita oggi... ha fatto un balzo in intra...

neppure a me convince...

magari parte e non si ferma + :D


porcaccia la miseria stai a vedere che parte davvero..

9,16 17:41:52 3,15%

:D :D :D
 
io ci provo..

entrato (In ritardo come al solito) 9,4$

BigNick
 
Prevista per oggi

Immunomedics to Present at the Bear Stearns 16th Annual HealthcareConference

MORRIS PLAINS, N.J., Sep 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Immunomedics, Inc. (Nasdaq: IMMU) announced today that it will make a presentation at the Bear Stearns 16th Annual Healthcare Conference on Tuesday September 9, 2003 at 3:30 p.m. Eastern Daylight Time (EDT). The conference is being held at The Plaza Hotel, 5th Avenue and Central Park South, New York, NY. Cynthia L. Sullivan, President and Chief Executive Officer will present on the Company's business.

Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of disease. Immunomedics has six therapeutic product candidates in clinical trials and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide(R) (epratuzumab), certain rights to which have been licensed to Amgen, which is conducting Phase II clinical trials for the treatment of non-Hodgkin's lymphoma, and CEA-Cide(R) (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.
 
Re: io ci provo..

Scritto da BigNick
entrato (In ritardo come al solito) 9,4$

BigNick

proprio una bella entrata la mia, praticamente ai massimi, e si che ero entrato in ritardo :D :D

va beh, sembrerebbe aver trovato supporto sulla media 100, come già era successo in agosto, mi verrebe quasi voglia di mediarle, nessuno le segue più ?
 

Allegati

  • immu3.gif
    immu3.gif
    22,2 KB · Visite: 250
+8%

OVVIAMENTE non le ho mediate !
 
segni di ripresa...

8,52$ +6,23%
 
effettuato piccolo acquisto a 3,71 (ora e' a 3,68)
 
ti seguo bazar,,,,,,,

effettuato un'acquisto a 3,70,,,,,,,1000pz........

stasera credo di chiudere l'operazione,,,,,,in vincita o in perdita,,,,,,,,,,
 
Immunomedics In Talks To Regain Development Rights From Amgen For Epratuzumab



MORRIS PLAIN, N.J. -(Dow Jones)- Immunomedics Inc.(NASDAQ-NMS:IMMU) (IMMU) said it's in advanced talks to regain development rights to the advanced therapeutic product, epratuzumab, which was licensed to Amgen Inc.(NASDAQ-NMS:AMGN) (AMGN) three years ago.

Immunomedics' Nasdaq-traded stock was recently halted at $7.25.

The companies were looking to negotiate an expanded license agreement a few months ago that would have given Amgen worldwide development rights but the two couldn't agree on terms.

Recently, Amgen told Immunomedics it wouldn't proceed with a registration trial after reassessing its product portfolio.

But Immunomedics said in a press release Tuesday both companies agree "that the foremost objective is the continued development and commercialization of epratuzumab, only now potentially on a worldwide basis."

Immunomedics added that it's too early to determine the outcome of its talks with Amgen but hopes to be in a position to identify an appropriate licensing partner without delay.

The company also doesn't expect the change to affect ongoing trials being pursued by two of National Cancer Institute's study groups.

In both single- and multicenter clinical trials of epratuzumab given alone or in combination with rituximab, the agent has been found to be safe, well- tolerated in one-hour infusions and active in treating non-Hodgkins lymphoma patients.

Additional clinical data is also being presented by Amgen investigators at the forthcoming meeting of the American Society of Hematology, that will show further evidence of both the safety and activity of epratuzumab in non-Hodgkins lymphoma, Immunomedics said.

The company also added that it has early evidence that the agent is also well- tolerated in patients with autoimmune disease and is moving forward to complete the single-agent Phase I trial in these potentially new indications.

The company's stock resumed trading. Recently, the stock was trading at $4.36, down $2.89 or 39.9%.

-Freddy Sebastian; Dow Jones Newswires; 201-938-5400
 
gia' vista la stessa storia con vxgn,,,,,imcl,,,,,,

questi stanno facendo spurgare la bambola,,,,,,

i suoi conti non giustificano questa botta secondo me costruita,,,,,

se verra' qualche altro partner,,con qualche accordo rischizz in un niente a 10 dollari,,,,,,,,,


la storia si ripete,,,,,,o almeno me lo auguro,,,,,,,

vediamo che accade
 
Indietro